Gilead Sciences Is Acquiring Arcellx and Partnered Multiple Myeloma Drug in $7.8B DealNews DeskFebruary 23, 20260 Gilead Sciences is expanding its cell therapy pipeline and technological capabilities through the $7.8 billion acquisition of Arcellx, its partner…